Instil Bio, Inc. (TIL)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-15) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-27) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-13) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-13) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-13) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-04) · 99.1 · 99.2 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-13) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-13) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-10) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-21) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-13) · 99.1 | ||
| 10-Q/A | Q3-2023 | |||
| 10-Q | Q2-2023 | 8-K (2023-08-14) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Stockholders Equity | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Stockholders Equity (P) | ||
| Consolidated Statements of Cash Flows (P) | ||
| Notes | ||
| Balance Sheet Components | ||
| Commitments and Contingencies | ||
| Corporate Restructuring | — |
|
| Corporate Restructuring Plan | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Equity | ||
| Fair Value Measurement | ||
| Financial Instruments | ||
| Goodwill and Intangible Assets | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| License and Collaboration Agreement With Immuneonco | ||
| Net Loss Per Share | ||
| Organization and Description of Business | ||
| Pay Vs Performance Disclosure | ||
| Restructuring and Impairment of Long-lived Assets | — |
|
| Segment Reporting | ||
| Stock-based Compensation | ||
| Subsequent Events | — |
|
| Summary of Significant Accounting Policies | ||